Texas Hepatocellular Carcinoma Consortium (THCCC)


About the Consortium


Hepatocellular cancer is the most common (>95 percent) of primary liver cancers. HCC is also the fastest rising cause of cancer-related deaths in the United States, and Texas has the highest death rate from HCC in the nation. The five-year HCC survival remains low (10-15 percent) and most patients get diagnosed at late stages. Texas residents notably Hispanics and African Americans are greatly affected with established HCC risk factors including hepatitis C virus, hepatitis B virus and alcoholic liver disease. Furthermore, emerging HCC risk factors, specifically the metabolic syndrome and non-alcoholic fatty liver disease (NAFLD), are exceptionally common in Texans.

The Texas Hepatocellular Carcinoma Consortium was established in 2015 to reduce the burden and mortality of hepatocellular cancer (HCC) in Texas. Building on the Quality in the Continuum of Cancer Care framework, our proposed THCCC targets key areas of uncertainty in the prevention and early detection of HCC. The THCCC includes researchers, clinicians, and staff from Baylor College of Medicine, Veterans Affairs, MD Anderson Cancer Center, UT Southwestern Medical Center, Parkland Health Hospital System in Dallas, and UT San Antonio. Our cohort has become the largest ongoing prospective cohort of patients with cirrhosis in the nation.



The THCCC is made possible by grant RP150587 from the Cancer Prevention and Research Institute of Texas, PI: Hashem B. El-Serag; P01 CA263025 from the National Cancer Institutes, PI: Hashem B. El-Serag; and RP220119 from the Cancer Prevention and Research Institute of Texas, PI Hashem B. El-Serag. It is also supported by U01 CA230997-01, PI: Fasiha Kanwal.

Learn More

THCCC Cores & Projects

  • Core 1 - The Cohorts and Samples Core
  • Core 2 - The Statistical Coordinating Core
  • Project 1 - Risk Factors of HCC in NAFLD
  • Project 2 - Metabolic Syndrome and Risk Prediction
  • Project 3 - Circadian Disruption and Bile Acids
  • Project 4 - Novel Biomarkers for HCC
  • Project 5 - Randomized Controlled Trial
Learn More


Media Component
Dan L Duncan Comprehensive Cancer Center Front Desk

Baylor receives NCI grant to study liver cancer risk and prevention
Aug. 4, 2022: Researchers at Baylor College of Medicine received a five-year, $5.5 million-plus grant from the National Cancer Institute for research on liver cancer risk factors and prevention, with the goal of reducing the burden of liver cancer in patients with metabolic dysfunction.

Baylor receives more than $15.6 million in CPRIT funding
Feb. 17, 2022: Researchers with the Dan L Duncan Comprehensive Cancer Center at Baylor College of Medicine have been awarded more than $15.6 million in grants by the Cancer Prevention & Research Institute of Texas (CPRIT) to support innovative cancer research, treatment and prevention measures for underserved populations.

Back to topback-to-top